

In-Vitro Diagnostics (IVD) Market Analysis and Segment Forecasts To 2020

https://marketpublishers.com/r/IB238275766EN.html

Date: March 2014

Pages: 78

Price: US\$ 4,450.00 (Single User License)

ID: IB238275766EN

Abstracts

The global market for IVD is expected to reach USD 74.32 billion by 2020. Constantly improving patient awareness levels pertaining to infectious diseases and their subsequent diagnosis, the introduction of advanced molecular and tissue diagnostic tests for cancer such as companion diagnostics and the growing global base of geriatric population are some of the primary drivers for this market. Moreover, rising global healthcare expenditures, especially in Asia Pacific and increasing demand for rapid, minimally invasive and non-invasive diagnostic procedures are also expected to have a positive impact on market growth. The emergence of epigenomics-based diagnostics and the ability of molecular diagnostics to detect disease at an early stage of development are expected to create opportunity for industry participants to capitalize on over the next six years.

The professional diagnostic products dominated the overall IVD market in 2013, owing to the high usage rates of these tests in diagnostic tests pertaining to the infectious disease segment, and are expected to grow at a CAGR of 4.7% from 2014 to 2020 to reach an estimated value of USD 49.76 billion by 2020. However, the tissue diagnostics market is expected to grow at the highest CAGR of 10.2% from 2014 to 2020, owing to its growing application in cancer diagnosis and need for lab automation as a consequence of limited skilled labor availability.

Further Key findings from the study suggest:

North America is expected to dominate the overall market throughout the forecast period, majorly on account of the presence of sophisticated healthcare infrastructure, high patient awareness levels and improving reimbursement frameworks, with revenue estimated to reach USD 28.79 billion by 2020.



Asia Pacific is expected to be the fastest growing regional market for IVD, at an estimated CAGR of 7.4% from 2014 to 2020. The presence of high unmet medical needs for cancer and infectious diseases and a constantly improving healthcare infrastructure in emerging markets such as China and India are some of the drivers of this market.

The global molecular diagnostics market is expected to follow the tissue diagnostics segment in terms of growth during the forecast period, owing to the growing demand for advanced genetic and HPV diagnostic tests. Its market is expected to grow at a CAGR of 8.7% from 2014 to 2020.

Some of the key players of this market include Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, bioMerieux, Beckman Coulter Inc., Becton Dickinson and others

For the purpose of this study, Grand View Research has segmented the global IVD market on the basis of product and region:

IVD Market Product Outlook
Molecular Diagnostics
Tissue Diagnostics
Diabetes Monitoring
Professional Diagnostics
IVD Market Regional Outlook
North America
Europe
Asia Pacific

RoW



Contents

CHAPTER 1. EXECUTIVE SUMMARY

1.1. IVD - Industry Summary and Critical Success Factors (CSFs)

CHAPTER 2. IVD INDUSTRY OUTLOOK

- 2.1. Market Segmentation
- 2.2. Market Size and Growth Prospects
- 2.3. IVD Market Dynamics
- 2.4. Key Opportunities Prioritized
- 2.5. Industry Analysis Porter's
- 2.6. Molecular Diagnostics Company Market Share Analysis
- 2.7. Tissue Diagnostics Company Market Share Analysis
- 2.8. Professional Diagnostics Company Market Share Analysis
- 2.9. Diabetes Monitoring Company Market Share Analysis
- 2.10. IVD Market PESTEL Analysis, 2012

CHAPTER 3. IVD PRODUCT OUTLOOK

- 3.1. Molecular Diagnostics
- 3.2. Tissue Diagnostics
- 3.3. Diabetes Monitoring
- 3.4. Professional Diagnostics

CHAPTER 4. IVD REGIONAL OUTLOOK

- 4.1. North America
- 4.2. Europe
- 4.3. Asia-Pacific
- 4.4. RoW

CHAPTER 5. COMPETITIVE LANDSCAPE

- 5.1 Abbott Laboratories
 - 5.1.1 Company Overview
 - 5.1.2 Financial Performance
 - 5.1.3 Product Benchmarking



- 5.1.4 Strategic Initiatives
- 5.2 Roche Diagnostics
 - 5.2.1 Company Overview
 - 5.2.2 Financial Performance
 - 5.2.3 Product Benchmarking
 - 5.2.4 Strategic Initiatives
- 5.3 Siemens Healthcare
 - 5.3.1 Company Overview
 - 5.3.2 Financial Performance
 - 5.3.3 Product Benchmarking
 - 5.3.4 Strategic Initiatives
- 5.4 Johnson and Johnson
 - 5.4.1 Company Overview
 - 5.4.2 Financial Performance
 - 5.4.3 Product Benchmarking
 - 5.4.4 Strategic Initiatives
- 5.5 Bio-Rad Laboratories
 - 5.5.1 Company Overview
 - 5.5.2 Financial Performance
 - 5.5.3 Product Benchmarking
 - 5.5.4 Strategic Initiatives
- 5.6 Beckman Coulter Inc.
 - 5.6.1 Company Overview
 - 5.6.2 Financial Performance
 - 5.6.3 Product Benchmarking
 - 5.6.4 Strategic Initiatives
- 5.7 Becton Dickinson
 - 5.7.1 Company Overview
 - 5.7.2 Financial Performance
 - 5.7.3 Product Benchmarking
 - 5.7.4 Strategic Initiatives
- 5.8 bioMerieux
 - 5.8.1 Company Overview
 - 5.8.2 Financial Performance
 - 5.8.3 Product Benchmarking
 - 5.8.4 Strategic Initiatives
- 5.9 Sysmex
 - 5.9.1 Company Overview
 - 5.9.2 Financial Performance



- 5.9.3 Product Benchmarking
- 5.9.4 Strategic Initiatives
- 5.10 Bayer Healthcare
 - 5.10.1 Company Overview
 - 5.10.2 Financial Performance
 - 5.10.3 Product Benchmarking
 - 5.10.4 Strategic Initiatives
- 5.11 Alere Inc.
- 5.11 .1 Company Overview
 - 5.11.2 Financial Performance
 - 5.11.3 Product Benchmarking
 - 5.11.4 Strategic Initiatives
- 5.12 Danaher Corporation
 - 5.12.1 Company Overview
 - 5.12.2 Financial Performance
 - 5.12.3 Product Benchmarking
 - 5.12.4 Strategic Initiatives
- 5.13 Hologic (Gen-Probe)
 - 5.13.1 Company Overview
 - 5.13.2 Financial Performance
 - 5.13.3 Product Benchmarking
 - 5.13.4 Strategic Initiatives
- 5.14 Novartis
 - 5.14.1 Company Overview
 - 5.14.2 Financial Performance
 - 5.14.3 Product Benchmarking
 - 5.14.4 Strategic Initiatives
- 5.15 Cepheid
 - 5.15.1 Company Overview
 - 5.15.2 Financial Performance
 - 5.15.3 Product Benchmarking
 - 5.15.4 Strategic Initiatives
- 5.16 Qiagen
 - 5.16.1 Company Overview
 - 5.16.2 Financial Performance
 - 5.16.3 Product Benchmarking
 - 5.16.4 Strategic Initiatives
- 5.17 Leica Biosystems
- 5.17.1 Company Overview



- 5.17.2 Financial Performance
- 5.17.3 Product Benchmarking
- 5.17.4 Strategic Initiatives
- 5.18 Dako
 - 5.18.1 Company Overview
 - 5.18.2 Financial Performance
 - 5.18.3 Product Benchmarking
 - 5.18.4 Strategic Initiatives

CHAPTER 6. METHODOLOGY AND SCOPE

- 6.1. Research Methodology
- 6.2. Research Scope & Assumption
- 6.3. List of Data Sources



List Of Tables

LIST OF TABLES

- 1. IVD Industry Summary & Critical Success Factors (CSFs)
- 2. Global IVD Revenue, 2012 2020 (USD million)
- 3. Global IVD Market Revenue by Region, (USD million), 2012 2020
- 4. Global IVD Market Revenue by Products, (USD million), 2012 2020
- 5. Global Tissue Diagnostics Demand, 2012 to 2020 (USD million)
- 6. Global Tissue Diagnostics Demand, by Region, 2012 to 2020 (USD million)
- 7. Global Molecular Diagnostics Demand, 2012 to 2020 (USD million)
- 8. Global Molecular Diagnostics Demand, by Region, 2012 to 2020 (USD million)
- 9. Global Professional Diagnostics Demand, 2012 to 2020 (USD million)
- 10. Global Professional Diagnostics Demand, by Region, 2012 to 2020 (USD million)
- 11. Global Diabetes Monitoring Demand, 2012 to 2020 (USD million)
- 12. Global Diabetes Monitoring Demand, by Region, 2012 to 2020 (USD million)
- 13. North America IVD demand, by Products, (USD million), 2012 2020
- 14. Europe IVD demand, by Products, (USD million), 2012 2020
- 15. Asia Pacific IVD demand, by Products, (USD million), 2012 2020
- 16. RoW IVD demand, by Products, (USD million), 2012 2020



List Of Figures

LIST OF FIGURES

- 1. IVD Market Segmentation
- 2. Global IVD Market Revenue, 2012 2020
- 3. IVD Market Dynamics
- 4. Global population base over the age group of 60 years, 2010 and 2017 (million)
- 5. Global diabetes prevalence, 2010 and 2017 (million)
- 6. Molecular Diagnostics Company Market Share Analysis, 2012
- 7. Tissue Diagnostics Company Market Share Analysis, 2012
- 8. Professional Diagnostics Company Market Share Analysis, 2012
- 9. Diabetes Monitoring Company Market Share Analysis, 2012
- 10. Key Opportunities Prioritized
- 11. Industry Analysis Porter's
- 12. IVD PESTEL Analysis, 2012
- 13. Global IVD Revenue, by Products, 2012 & 2020
- 14. Global Molecular Diagnostics Demand, by Region, 2012 to 2020 (USD million)
- 15. Global Tissue Diagnostics Demand, by Region, 2012 to 2020 (USD million)
- 16. Global Professional Diagnostics Demand, by Region, 2012 to 2020 (USD million)
- 17. Global Diabetes Monitoring Demand, by Region, 2012 to 2020 (USD million)
- 18. North America IVD Demand, by Products, 2012 to 2020 (USD million)
- 19. Europe IVD Demand, by Products, 2012 to 2020 (USD million)
- 20. Asia Pacific IVD Demand, by Products, 2012 to 2020 (USD million)
- 21. RoW IVD Demand, by Products, 2012 to 2020 (USD million)



I would like to order

Product name: In-Vitro Diagnostics (IVD) Market Analysis and Segment Forecasts To 2020

Product link: https://marketpublishers.com/r/IB238275766EN.html

Price: US\$ 4,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/IB238275766EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970